Aprea Therapeutics Strengthens Global Patent Portfolio in DNA Damage Response (DDR) Cancer Therapeutics, Paving Way for Pipeline Growth

Core Insights - Aprea Therapeutics has expanded its global intellectual property estate with new patents granted in 2025 in Australia and Japan, enhancing protection for its WEE1 and ATR programs, expected to provide exclusivity until 2045 [1][3] - The lead WEE1 inhibitor candidate, APR-1051, is currently in Phase 1 trials, showing early clinical proof of concept, with multiple data readouts anticipated in 2026 [1][3] - Aprea's robust patent strategy aims to secure long-term commercial value and de-risk clinical development by protecting proprietary molecules and therapeutic applications [2][3] WEE1 Program - The WEE1 inhibitor APR-1051 is being evaluated in the ACESOT-1051 Phase 1 clinical trial for advanced/metastatic solid tumors with specific gene alterations [3] - The WEE1 patent portfolio includes one provisional U.S. patent application, two pending U.S. applications, one issued patent in Australia, and 13 pending applications internationally, with core patents expected to provide protection through 2042 [3] ATR Program - The ATR inhibitor ATRN-119 is under evaluation in the ABOYA-119 clinical trial as a monotherapy for patients with advanced solid tumors [4] - The ATR patent estate consists of four issued U.S. patents, one pending U.S. application, one international application, and 21 granted patents, including one issued in Japan in 2025, with existing patents expected to remain in force through 2035-2037 [4] Company Overview - Aprea is focused on developing innovative cancer therapies that exploit cancer-specific vulnerabilities while minimizing damage to healthy cells, aiming to reduce toxicity associated with traditional treatments [6] - The company's lead programs, APR-1051 and ATRN-119, are small-molecule inhibitors targeting solid tumor indications [7]